Ikena Oncology, Inc. logo

Ikena Oncology, Inc.

NASDAQ:IKNA

Overview | Financials
Company Name Ikena Oncology, Inc.
Symbol IKNA
Currency USD
Price 17.16
Market Cap 718,823,820
Dividend Yield 0%
52-week-range 1.36 - 23.28
Industry Biotechnology
Sector Healthcare
CEO Dr. Mark Manfredi Ph.D.
Website https://ikenaoncology.com

An error occurred while fetching data.

About Ikena Oncology, Inc.

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing

Related Stocks

IO Biotech, Inc. logo

IO Biotech, Inc.

IOBT

2.12 USD

Assertio Holdings, Inc. logo

Assertio Holdings, Inc.

ASRT

0.704 USD

DarioHealth Corp. logo

DarioHealth Corp.

DRIO

0.578 USD

AVITA Medical, Inc. logo

AVITA Medical, Inc.

RCEL

9.96 USD

Sol-Gel Technologies Ltd. logo

Sol-Gel Technologies Ltd.

SLGL

12.48 USD

Citius Pharmaceuticals, Inc. logo

Citius Pharmaceuticals, Inc.

CTXR

1.39 USD

Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc.

OVID

0.5 USD

ProPhase Labs, Inc. logo

ProPhase Labs, Inc.

PRPH

0.356 USD

Financials

Numbers are in millions USD

Numbers are in millions USD